Press Releases

Date Title and Summary Additional Formats
Toggle Summary Argos Therapeutics Announces New Data Demonstrating Prolonged Overall Survival in a Phase 2 Study of its Arcelis™ Immunotherapy AGS-003 in Combination with Sunitinib in Patients with Metastatic Renal Cell Carcinoma (mRCC)
-Results Support Planned, Randomized Phase 3 ADAPT Study
View HTML
Toggle Summary Argos Therapeutics Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
View HTML
Toggle Summary Argos Therapeutics´ Late Scientific Co-founder Ralph Steinman, M.D., Awarded Nobel Prize in Medicine for Discovery of Dendritic Cells as Critical Sentinels of Immune System
View HTML
Toggle Summary Argos Therapeutics Files Registration Statement for Proposed Initial Public Offering
View HTML
Toggle Summary Argos Therapeutics to Participate in Panel Discussion on Innovative Approaches to HIV Vaccine Development and Immunotherapies at 2011 BIO International Convention
View HTML
Toggle Summary Argos Therapeutics Presents New Phase 2 Data Showing its Arcelis™ Immunotherapy AGS-003 in Combination with Sunitinib Improves Progression-Free Survival (PFS) in Patients with Advanced Renal Cell Carcinoma (RCC)
View HTML
Toggle Summary Argos Therapeutics´ Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination with Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
View HTML
Toggle Summary Argos Therapeutics´ Immunotherapy Platform Based on Recombinant Human Soluble CD83 Demonstrates Significant Promise For Solid Organ Transplantation
View HTML
Toggle Summary Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Needham & Company 10th Annual Healthcare Conference and Leerink Swann Cancer Roundtable Conference
View HTML
Toggle Summary Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics´ Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
View HTML

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

Tweets